Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,442,697
  • Shares Outstanding, K 101,670
  • Annual Sales, $ 36,570 K
  • Annual Income, $ -54,570 K
  • 36-Month Beta 2.97
  • Price/Sales 39.46
  • Price/Cash Flow N/A
  • Price/Book 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.13
  • Number of Estimates 5
  • High Estimate 0.07
  • Low Estimate -0.24
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.31 +4.36%
on 10/11/18
17.35 -19.94%
on 09/28/18
-1.46 (-9.51%)
since 09/19/18
3-Month
12.60 +10.24%
on 09/06/18
19.25 -27.84%
on 09/04/18
-1.16 (-7.71%)
since 07/19/18
52-Week
11.30 +22.92%
on 10/26/17
27.50 -49.49%
on 02/22/18
-0.06 (-0.43%)
since 10/19/17

Most Recent Stories

More News
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors

To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.

SGMO : 13.89 (-2.11%)
ABBV : 87.97 (-2.15%)
GILD : 73.27 (-1.21%)
GSK : 40.87 (+3.18%)
Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) today jointly announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of EUR 2.58 per share...

SGMO : 13.89 (-2.11%)
Interesting SGMO Put And Call Options For May 2019

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the May 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

SGMO : 13.89 (-2.11%)
Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options

Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

SGMO : 13.89 (-2.11%)
Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences in September and October.

SGMO : 13.89 (-2.11%)
Major Stem Cell Breakthroughs Giving Investors Big Opportunity

HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is...

SGMO : 13.89 (-2.11%)
CARA : 19.67 (-1.45%)
GERN : 1.67 (-2.34%)
Gilead Inks Gene Editing Collaboration Deal for HBV Infection

Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.

SGMO : 13.89 (-2.11%)
LGND : 187.52 (-4.84%)
GILD : 73.27 (-1.21%)
GLPG : 107.73 (+2.50%)
Gilead's Rheumatoid Arthritis Drug Successful in Phase III

Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.

SGMO : 13.89 (-2.11%)
GILD : 73.27 (-1.21%)
GLPG : 107.73 (+2.50%)
GSK : 40.87 (+3.18%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (PTCT , TTOO, SGMO , PBYI , MRTX)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

PTCT : 38.00 (-3.31%)
SGMO : 13.89 (-2.11%)
TTOO : 4.74 (-5.20%)
MRTX : 40.01 (-4.42%)
Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

SGMO : 13.89 (-2.11%)
GILD : 73.27 (-1.21%)
GLPG : 107.73 (+2.50%)
GSK : 40.87 (+3.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade SGMO with:

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

2nd Resistance Point 14.83
1st Resistance Point 14.36
Last Price 13.89
1st Support Level 13.64
2nd Support Level 13.39

See More

52-Week High 27.50
Fibonacci 61.8% 21.31
Fibonacci 50% 19.40
Fibonacci 38.2% 17.49
Last Price 13.89
52-Week Low 11.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar